Thyrocare Technologies Limited

BSE:539871 Stock Report

Market Cap: ₹71.9b

Thyrocare Technologies Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Rahul Guha

Chief executive officer

₹56.4m

Total compensation

CEO salary percentage74.26%
CEO tenure4yrs
CEO ownership0.1%
Management average tenureless than a year
Board average tenure2.8yrs

Recent management updates

Recent updates

Narrative Update • Apr 28

539871: Stable Return Assumptions Will Support Bullish Medium Term View

Analysts have kept Thyrocare Technologies' fair value estimate steady at ₹571.67 per share, with only small tweaks to inputs such as expected revenue growth, profit margin, and future P/E assumptions driving this unchanged price target. Valuation Changes Fair Value: Kept unchanged at ₹571.67 per share, indicating no net impact from the latest input updates.
Narrative Update • Apr 09

539871: Stable Assumptions And Upcoming Results Will Support Bullish View

Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E in their latest update. What's in the News A board meeting is scheduled on January 28, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Narrative Update • Mar 25

539871: Stable Assumptions And Upcoming Results Will Support Bullish Outlook

Analysts have kept their price target for Thyrocare Technologies broadly unchanged at around ₹572. This reflects stable assumptions on discount rate, revenue growth, profit margin and future P/E in their valuation work.
Narrative Update • Mar 11

539871: Steady Assumptions And Upcoming Results Will Support Future Returns

Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting largely unchanged views on fair value, discount rate, growth and profit assumptions. What's in the News Board meeting scheduled for January 28, 2026, to review and consider the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).
Narrative Update • Feb 24

539871: Steady Assumptions And Upcoming Results Will Support Future Returns

Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margins and future P/E in their updated work. What's in the News A board meeting is scheduled for January 28, 2026, to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Narrative Update • Feb 10

539871: Capitalisation Flexibility And Updated Profit Assumptions Will Support Returns

Analysts have slightly revised their price target on Thyrocare Technologies to ₹571.67, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that are now modestly lower than previously assumed. What's in the News Board meeting scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).
Narrative Update • Jan 26

539871: Capitalisation Flexibility And Higher Future P/E Will Support Returns

Analysts have nudged their fair value estimate for Thyrocare Technologies higher from ₹560.56 to ₹571.67, reflecting updated views on its long term revenue growth, profit margins and future P/E assumptions. What's in the News A board meeting is scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).
Narrative Update • Jan 10

539871: Stock Split And Bonus Share Flexibility Will Support Future Returns

Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹506.67 to ₹560.56, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board approval has been sought via a postal ballot dated October 14, 2025 to increase authorised share capital to INR 3,000,000,000, split into 300,000,000 equity shares of INR 10 each, with related changes to the Memorandum and Articles of Association (company filing).
Narrative Update • Dec 26

539871: Stock Split And Bonus Capacity Will Drive Future Shareholder Returns

Analysts have maintained their price target for Thyrocare Technologies at ₹506.67 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News The board approved a proposal to increase authorised share capital and amend the Memorandum of Association and Articles of Association, subject to shareholder approval (Board Meeting, October 14, 2025, Key Developments).
Narrative Update • Dec 11

539871: Bonus Share And Stock Split Plan Will Drive Future Shareholder Value

Analysts have sharply reduced their price target on Thyrocare Technologies to approximately ₹507 from about ₹1,520. This reflects a recalibrated fair value framework even as underlying assumptions for growth, margins, discount rate and future valuation multiples remain largely unchanged.
Narrative Update • Nov 27

539871: Upcoming Board Approvals And Dividend Proposals Will Shape Shareholder Value

Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹1,520 per share, citing stable outlooks in revenue growth and profit margins as the key drivers behind the unchanged price target. What's in the News The board meeting on October 14, 2025 considered and approved unaudited financial results for the quarter and half year ended September 30, 2025.
Narrative Update • Nov 12

539871: Upcoming Board Decisions And Shareholder Actions Will Influence Outlook

Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable expectations for revenue growth, profit margin, and valuation metrics. What's in the News Special or Extraordinary Shareholders Meeting scheduled for November 16, 2025, to be conducted via postal ballot in India (Key Developments).
Narrative Update • Oct 29

Upcoming Bonus Shares And Dividend Proposal Will Drive Shareholder Value

Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable revenue growth projections along with only minor adjustments in profit margin and future valuation metrics. What's in the News The board meeting was held on October 14, 2025 to approve unaudited financial results, consider the declaration of an interim dividend, and review a proposal for the issue of bonus shares (Board Meeting).
Narrative Update • Oct 15

Franchise Expansion And PharmEasy Partnerships Will Secure Future Success

Analysts have raised their fair value estimate for Thyrocare Technologies from ₹1,355 to ₹1,520. They cite improved profit margins and expectations of sustainable earnings, even though revenue growth is moderating.
Narrative Update • Sep 05

Franchise Expansion And PharmEasy Partnerships Will Secure Future Success

With both Net Profit Margin and Future P/E ratio remaining stable, analysts have kept Thyrocare Technologies’ fair value unchanged at ₹1355. What's in the News Special/Extraordinary Shareholders Meeting scheduled via postal ballot in India.
User avatar
New Narrative • Jan 26

Integrating Vimta Labs And Achieving 100% NABL Accreditation Will Position The Company As An Industry Leader

Expanding geographical presence and strategic acquisitions are expected to drive future revenue growth and enhance service offerings.

CEO Compensation Analysis

How has Rahul Guha's remuneration changed compared to Thyrocare Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

₹2b

Dec 31 2025n/an/a

₹1b

Sep 30 2025n/an/a

₹1b

Jun 30 2025n/an/a

₹1b

Mar 31 2025₹56m₹42m

₹915m

Dec 31 2024n/an/a

₹877m

Sep 30 2024n/an/a

₹840m

Jun 30 2024n/an/a

₹776m

Mar 31 2024₹35m₹14m

₹708m

Dec 31 2023n/an/a

₹655m

Sep 30 2023n/an/a

₹648m

Jun 30 2023n/an/a

₹599m

Mar 31 2023₹32mn/a

₹645m

Compensation vs Market: Rahul's total compensation ($USD584.78K) is above average for companies of similar size in the Indian market ($USD390.58K).

Compensation vs Earnings: Rahul's compensation has increased by more than 20% in the past year.

CEO

Rahul Guha (47 yo)

4yrs
Tenure
₹56,353,536
Compensation

Mr. Rahul Franklin Guha served as President of Operations at API Holdings Limited since 2024 and serves as its Managing Director and Chief Executive Officer since August 27, 2025 and its Director since Aug...

Leadership Team

NamePositionTenureCompensationOwnership
Rahul Guha
MD, CEO & Chairman4yrs₹56.35m0.11%
₹ 81.3m
Brijesh Kumar
Company Secretary & Compliance Officer1.3yrs₹686.25kno data
Vikram Gupta
Chief Financial Officerless than a yearno datano data
Ramesh Kinha
Chief Operating Officerless than a yearno datano data
Pratik Hire
Head of Strategy & Investor Relationsno datano datano data
Rajdeep Panwar
Chief Commercial Officerless than a yearno datano data
Aditya Shinde
Vice Presidentno data₹5.33mno data
Kapil Gupta
Strategy Managerno datano datano data
Preet Kaur
Vice President of Lab Operations & Qualityno datano datano data
Preet Joshi
Strategy Managerno datano datano data
0.8yrs
Average Tenure
42yo
Average Age

Experienced Management: 539871's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Rahul Guha
MD, CEO & Chairman4yrs₹56.35m0.11%
₹ 81.3m
Indumati Gopinathan
Non-Executive Independent Director8.8yrs₹600.00kno data
Prapti Gilada
Independent Director2.8yrs₹800.00kno data
Harshil Vora
Non-Executive Independent Director2.8yrs₹300.00kno data
Alok Jagnani
Additional Non-Executive & Non-Independent Directorless than a year₹11.88mno data
Anandh Sundar
Independent Director1.9yrs₹350.00kno data
Nishant Shah
Independent Director1.9yrs₹350.00kno data
2.8yrs
Average Tenure
45yo
Average Age

Experienced Board: 539871's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/18 09:14
End of Day Share Price 2026/05/18 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Thyrocare Technologies Limited is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alka Katiyar360 ONE Capital Market Private Limited
Rahul AgarwalCGS International
Kameswari V. S. ChavaliFirstCall Research